3-[4-(6-(3-(dimethylamino)propoxy)benzo[d]oxazol-2-yl)phenoxy]-N,N-dimethylpropan-1-amine | 1219962-49-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-[4-(6-(3-(dimethylamino)propoxy)benzo[d]oxazol-2-yl)phenoxy]-N,N-dimethylpropan-1-amine
• 英文别名: AT791；3-(4-(6-(3-(Dimethylamino)propoxy)benzo[d]oxazol-2-yl)phenoxy)-N,N-dimethylpropan-1-amine；3-[4-[6-[3-(dimethylamino)propoxy]-1,3-benzoxazol-2-yl]phenoxy]-N,N-dimethylpropan-1-amine
• CAS: 1219962-49-8
• 化学式: C₂₃H₃₁N₃O₃
• 分子量: 397.517
• InChiKey: JKFYWFWUJUHSMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  29
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  51
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] BENZOXAZOLE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS BENZOXAZOLE ET PROCÉDÉS D'UTILISATION
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2010036905A1

  公开（公告）日：2010-04-01

  The present invention provides benzoxazole compounds and pharmaceutically acceptable salts thereof and pharmaceutical compositions including the same. The present invention further provides methods of use as described herein.

  本发明提供苯并噁唑化合物及其药用可接受盐和包括其在内的药物组合物。本发明还提供如本文所述的使用方法。
• BENZOXAZOLE COMPOUNDS AND METHODS OF USE
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2350032B1

  公开（公告）日：2016-05-25
• COMBINATION THERAPIES
  申请人：INFINITY PHARMACEUTICALS, INC.

  公开号：US20150320754A1

  公开（公告）日：2015-11-12

  Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor, or pharmaceutically acceptable form thereof, in combination with a second agent, or a pharmaceutically acceptable form thereof, wherein the second agent is chosen from one or more of 1) a CDK4/6 inhibitor, 2) an HDAC inhibitor, 3) a MEK inhibitor, 4) a mTOR inhibitor, 5) an AKT inhibitor, 6) a proteasome inhibitor, 7) an immunomodulator, 8) a glucocorticosteroid, 9) a BET inhibitor, 10) an epigenetic inhibitor, 11) a PI3K alpha inhibitor, 12) a topoisomerase inhibitor, or 13) an ERK inhibitor. Also provided herein are methods of treatment comprising administration of the compositions, and uses of the compositions, e.g., for treatment of cancer.
• SAFE DELIVERY OF CRISPR AND OTHER GENE THERAPIES TO LARGE FRACTIONS OF SOMATIC CELLS IN HUMANS AND ANIMALS
  申请人：Hanley Brian P.

  公开号：US20200325483A1

  公开（公告）日：2020-10-15

  A method for making it possible to deliver nucleic acid sequences to a large fraction of, or even 99.9% and more of the cells in a human body without near certainty of killing the recipient. It can be applied to safely deliver any gene therapy. This invention comprises a set of known compounds, many of them already approved, combined in novel ways to prevent immune system reaction to levels of delivery vehicle (capsid or synthetic carrier) introduced into the body that can be 5 or more orders of magnitude higher than has been demonstrated to cause human death. When used in concert with the disclosed CRISPR expression control method, this method can improve expression and allow better control over the gene therapy's target activity.
• US8354400B2
  申请人：——

  公开号：US8354400B2

  公开（公告）日：2013-01-15